Key Points
- Director Darwin Lewis purchased 3,955 shares on Feb. 9 at an average price of $5.22 ($20,645.10), increasing his holding to 135,508 shares (a 3.01% rise).
- LifeVantage missed quarterly estimates, reporting EPS of $0.15 vs. $0.22 expected and revenue of $48.93M vs. $54.4M, and set FY2026 guidance of $0.60–$0.80 EPS.
- The company declared a quarterly dividend of $0.045 per share (annualized $0.18), implying a ~3.5% yield, with record date Mar. 2 and payment on Mar. 16.
Lifevantage Corporation (NASDAQ:LFVN - Get Free Report) Director Darwin Lewis acquired 3,955 shares of the company's stock in a transaction on Monday, February 9th. The stock was acquired at an average price of $5.22 per share, with a total value of $20,645.10. Following the acquisition, the director owned 135,508 shares in the company, valued at approximately $707,351.76. This trade represents a 3.01% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Darwin Lewis also recently made the following trade(s):
- On Monday, December 15th, Darwin Lewis bought 805 shares of Lifevantage stock. The shares were acquired at an average cost of $6.54 per share, for a total transaction of $5,264.70.
Lifevantage Stock Up 3.2%
Shares of Lifevantage stock opened at $5.09 on Thursday. The business has a 50 day moving average of $6.05 and a 200 day moving average of $8.67. Lifevantage Corporation has a 52 week low of $3.90 and a 52 week high of $19.41. The company has a market cap of $65.10 million, a PE ratio of 8.48 and a beta of 0.33.
Lifevantage (NASDAQ:LFVN - Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.07). Lifevantage had a net margin of 3.74% and a return on equity of 29.59%. The company had revenue of $48.93 million during the quarter, compared to the consensus estimate of $54.40 million. Lifevantage has set its FY 2026 guidance at 0.600-0.800 EPS.
Lifevantage Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, March 16th. Investors of record on Monday, March 2nd will be given a dividend of $0.045 per share. The ex-dividend date is Monday, March 2nd. This represents a $0.18 annualized dividend and a dividend yield of 3.5%. Lifevantage's payout ratio is currently 30.00%.
Institutional Trading of Lifevantage
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Capital Management Corp VA raised its stake in Lifevantage by 63.0% during the third quarter. Capital Management Corp VA now owns 2,064,176 shares of the company's stock valued at $20,084,000 after buying an additional 798,066 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Lifevantage in the second quarter worth $288,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Lifevantage during the second quarter valued at $784,000. AlphaQuest LLC raised its position in shares of Lifevantage by 12,659.7% in the 2nd quarter. AlphaQuest LLC now owns 7,911 shares of the company's stock worth $103,000 after purchasing an additional 7,849 shares during the last quarter. Finally, Navellier & Associates Inc. bought a new position in Lifevantage in the 3rd quarter worth about $480,000. Hedge funds and other institutional investors own 35.32% of the company's stock.
Analysts Set New Price Targets
Several analysts have weighed in on the company. Loop Capital set a $5.00 price objective on Lifevantage in a research report on Thursday, February 5th. Weiss Ratings restated a "hold (c)" rating on shares of Lifevantage in a research report on Monday, December 29th. Wall Street Zen cut Lifevantage from a "buy" rating to a "hold" rating in a research note on Saturday, November 8th. Finally, Lake Street Capital reiterated a "buy" rating on shares of Lifevantage in a report on Thursday, February 5th. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $5.00.
Read Our Latest Stock Analysis on LFVN
About Lifevantage
(
Get Free Report)
LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company's flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.
Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
